Immunoglobulin metabolism has been studied in five patients with ataxia telangiectasia and in control subjects. Serum IgG levels were normal, increased, or decreased, reflecting normal, increased, or decreased synthetic rates, respectively. Serum IgM concentration was normal in three cases and slightly elevated in two cases. IgM turnover studies in the three cases with normal serum IgM levels showed normal IgM synthetic and catabolic rates. None of the five patients with ataxia telangiectasia had detectable serum IgA, and the maximum IgA synthetic rates possible for these patients were 0.3-10% of the normal mean synthetic rate (24 ± 15 mg/kg per day) of 12 control individuals. Three of the patients had normal IgA fractional catabolic rates: 22% of the intravascular pool per day vs. 25 ± 4% in controls. In two patients, fractional catabolic rates 4 and 20 times normal were found. In these cases, metabolic turnover, in vitro precipitation, radioimmunoelectrophoresis, and (or) the C¢la fixation and transfer test provided evidence for the presence of a circulating antibody directed against IgA causing immune elimination of the molecule. These studies suggest that therapy with exogenous IgA may not be possible in some patients with ataxia telangiectasia or in other subjects with dysgammaglobulinemia.
INTRODUCTION
The recognition of distinct immunoglobulin classes has led directly to studies of specific immunoglobu-lin metabolism and function. Ataxia telangiectasia is of considerable interest in this connection since it has been associated with IgA deficiency and other immunologic abnormalities (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
Ataxia telangiectasia is characterized by cerebellar ataxia and oculocutaneous telangiectasia (12, 13) . Associated clinical findings in some patients have been recurrent sinopulmonary infection (1, 5, 6) and reticuloendothelial neoplasm (2, 12) . Immunologic defects have been reported in many patients. These defects include: (a) delayed skin homograft rejection and decreased response to tuberculin-type skin antigens (2, 4, 10) ; (b) decreased circulating antibody response to antigenic stimulation (2, 9) ; (c) lymphocytopenia with abnormal lymph node architecture (2, 4, 6, 8) ; (d) thymic abnormalities including both absence of thymus and histologically abnormal thymus (2, 5) ; and (e) a somewhat heterogeneous dysgammaglobulinemia (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
Among the most striking of the immunologic defects is the dysgammaglobulinemia. Normal persons produce three major classes of immunoglobulins: IgG (Y2, yss), IgA (y1A, ,82A), and IgM (,82M, yM). In patients with ataxia telangiectasia who were studied to determine immunoglobulin levels (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , 43 of 58 showed marked reduction -or absence of IgA, whereas in 1 of 58 there was an increased IgA level, and in 14 of 58, normal levels were present. In the deficient or absent IgA group, three patients had an associated IgG deficiency (2) , and five others had borderline IgG decreases (2, 6) ; in addition, marginal increases in IgG levels have been seen (6) . Also within this group, at least 10 instances of increased IgM (2, 3, 6, 7) and two instances of decreased IgM levels have been recorded (2, 8) .
The Journal of Clinical Investigation Volume 47 1968 In the present study, the metabolism of the immunoglobulins was studied in five patients with ataxia telangiectasia. Immunoglobulin levels were measured in the serum of these patients with a specific immune precipitation technique. In addition, immunoglobulin turnover studies were performed to determine total body protein pools and rates of degradation and synthesis of the various immunoglobulins. A pronounced defect in IgA synthesis and, in some cases, a shortened survival of IgA was demonstrated in these patients with ataxia telangiectasia.
METHODS
Patient material. Five patients with ataxia telangiectasia were studied. A summary of pertinent clinical data is presented in Table I . Patients ranged in age from 11 to 19 yr; four of the five were females. The diagnosis was established by the presence of ataxia and ocular and (or) cutaneous telangiectasia. Extensive neurological evaluation was done in each case to exclude other causes of ataxia and other congenital neurologic diseases.
The infectious history of these patients is as follows: two patients (G.N.L. and G.V.L., ages 18 and 19) were without any significant history of recurrent infection. A third patient (P.G., age 14) gave a history of recurrent respiratory infection, including pneumonia, several years before admission (from age 6 to 9 yr), which was controlled with adequate pulmonary drainage; this patient had considerable difficulty controlling respiratory secretions. A fourth patient (D.R., age 10) had a history of chronic postnasal drip without evidence of sinusitis by x-ray; in the several weeks before study, she had a lowgrade fever which was never well explained; in this case there was a single episode of otitis media which led to adenoidectomy. The fifth patient (G.R., age 14) had a history of chronic cough without acute lower respiratory infection. All patients had normal chest films and chest examinations during the period of study.
IgA turnover studies were performed on three patients with abnormal IgA levels but who did not have ataxia telangiectasia. These included: (a) a 70 yr old woman with myeloma and IgA paraprotein who was on phenylalanine mustard therapy; (b) a 45 yr old woman with acquired "idiopathic" hypogammaglobulinemia; and (c) a 38 yr old woman with IgG hypergammaglobulinemia, isolated absence of serum IgA, and a history of respiratory infections.
Control patients. Normal volunteers were used as controls in IgG and IgM turnover studies. Patients with various neurological and neoplastic diseases were used as controls in IgA turnover studies. These included four patients with myotonic dystrophy, two patients with Measurement of serum immunoglobulin concentrations. Immunoglobulin concentrations were measured by a specific immune precipitation technique (14, 15) . Standard sera were kindly supplied to us by Dr. John Fahey. Normal values with this system and these materials were established with a panel of 50 control sera.
Preparation of labeled proteins
IgG. IgG was obtained by diethylaminoethyl (DEAE)cellulose chromatography by a method similar to that described by Fahey, McCoy, and Goulian (16) . Fresh, normal human serum was dialyzed against 0.005 M pH 8.0 phosphate buffer and chromatographed in a DEAE column with the same buffer. The initial protein peak obtained was utilized for isotopic labeling; this protein fraction contained no detectable contaminants in Ouchterlony double diffusion studies.
IgMi. IgM was isolated by block electrophoresis and
Sephadex chromatography as in the procedure utilized by Barth, Wochner, Waldmann, and Fahey (17) . Fresh, normal serum was concentrated and electrophoresed in a polyvinyl chloride,' polyvinyl chloride-polyvinyl acetate copolymer block 2 (sodium barbital buffer, pH 8.6) for 18 hr. The gamma globulin region of the block was eluted with saline and concentrated by ultrafiltration; the protein was then dialyzed against 1.0 M NaCl, 0.1 m Tris-HCl, pH 8 buffer, and placed on a Sephadex G-200 column3 equilibrated with the same buffer; the first half of the initial peak thus obtained was used for labeling.
The material contained no detectable contaminants in Ouchterlony double diffusion studies.
IgA. IgA was isolated by starch-block electrophoresis with serum obtained from a patient with an isolated elevation of IgA (courtesy of Dr. A. Solomon); this serum abnormality has been unassociated with other evidence of disease over a period of several years. 6 ml of serum was electrophoresed in polyvinyl chloride, polyvinyl chloride-polyvinyl acetate copolymer block for 18 hr. 1 cm strips toward the anodal side of the origin were separately eluted with saline and analyzed for protein content. Preparation A contained IgA with an IgG contamination of approximately 15%, as shown by radial immunodiffusion in agar. IgG was the only significant contaminant detected by Ouchterlony studies with antiserum to whole human serum. Preparation B contained IgA with a transferrin contaminant of approximately 11%. Trace amounts of beta lipoprotein and a-2-macroglobulin were also demonstrated in preparation B. Preparation of C contained no detectable contaminants by immunoelectrophoresis ( Fig. 1 ) and Ouchterlony analysis using antisera directed against a variety of plasma proteins. Ultracentrifugal studies with saline solvent showed a single 6.6S peak in preparation B, and the major 6.6S peak and minor 9S and 11S peaks in preparation A. (Ultracentrifugal studies were done several weeks after the preparation of the protein.)
Labeling of proteins and radioimmunoelectrophoresis. All proteins were labeled with 131I or 'I by the iodine monochloride method of McFarlane (18) . All preparations were calculated to have an average of less than one atom of iodine per molecule of protein and contained less than 2% nonprecipitable radioactivity. Normal human albumin was added to each preparation in order to prevent damage due to irradiation.
After labeling, IgA preparations were studied by radioimmunoelectrophoresis. In all preparations, the major band of radioactivity was represented by IgA. In preparation A, a small proportion of the radioactivity was associated with IgG, and in preparation B, a small amount of label was associated with transferrin. Preparation A was thus shown to be free of transferrin contaminant, and preparation B was shown to be free of IgG contaminant. Preparation C contained no labeled contaminants.
The purified IgM preparation was also studied by radioimmunoelectrophoresis and contained no labeled contaminants. Labeled IgM was mixed with normal serum and placed over a Sephadex G-200 column; radioactivity appeared in the initial protein peak which thus confirmed labeling of 19S components.
Turnover study protocol. Patients were studied on the wards of the National Cancer Institute of the National Institute of Neurological Diseases and Blindness. Patients were never acutely ill during the period of study, and repeated determinations of serum immunoglobulins were constant, which thus confirmed the presence of steady-state conditions.
Patients were placed on saturated potassium iodide solution in order to block thyroidal uptake of isotope. Isotope injections were done in individual patients sequentially or simultaneously, in each case with 1"I or "I isotopes. Each turnover study was initiated with the injection of 5-30 /Ac of isotopically labeled protein with a calibrated syringe. A 10 min sample was obtained for plasma volume determinations. Subsequently, daily samples were drawn for 10-30 days. Complete urine collections were also obtained after the initiation of the study.
Immunoglobulin Metabolism in Ataxia Telangiectasia
Urine aliquots and serum samples were counted in an automatic gamma ray well-type scintillation counter with a thallium-activated sodium iodide crystal with a pulse height analyzer. Data analysis. Analysis of the IgG and IgM kinetic data was based on the methods of Berson, Yalow, Schreiber, and Post (19) and Pearson, Veall, and Vetter (20) . With these methods, the total exchangeable protein pool, the fractional catabolic rate, and the synthetic (turnover) rate were determined.
The IgA kinetic data were analyzed by a method of compartmental analysis elaborated by Berman, Shahn, and Weiss (21) . This method utilizes a digital computer to fit data to compartmental models and was chosen in order to obtain meaningful estimates of catabolic rates in certain instances of rapid catabolism of IgA protein.
In Fig. 2 is a diagram of the compartmental model which "fit" the IgA turnover data obtained in these experiments. It is seen that the model consists of protein pools (compartments) and intercompartmental transfer constants (X4i) representing the fractional rate of movement of material between compartments. Compartment 1 represents the plasma protein pool, compartment 2 represents the extravascular protein pool, compartment 3 represents the body iodide pool, compartment 4 represents the urinary radioiodide pool, and compartment 6 is a pool, parallel to compartment 1, which represents contaminant protein having an assigned fractional catabolic rate (asp). Conditions in compartments 1 and 4 were obtained from the IgA turnover data and were used by the computer to calculate conditions in the remaining compartments as well as the intercompartmental transfer constants. The initial pulse of radioactivity was distributed between compartments 1 and 6. The best fit of data to the compartmental model was obtained when approximately 15% of the initial dose was shunted into the contaminant pool (compartment 6) for preparations A and B; this corresponded well with the immunologic analyses of the original protein preparations. No contaminant pathway was necessary for preparation C. The transfer constant between compartments 1 and 3 (x3,1) represents the fractional degradation rate or the fraction of circulating IgA catabolized per day. The distribution of IgA between intra-and extravascular pools may be computed from the ratio of the transfer constants between pools 1 and 2 (X,2/X2i). The steady-state synthetic rate is the product of the fraction of the circulating IgA catabolized per day (xa) and the total circulating IgA.
It should be noted that the iodide excretion rate (x4, 8) was specified in the computer program within statistical limits with known experimental values (22) . In addition, the fractional catabolic rate of the contaminant proteins in preparations A and B (X3,4) was specified in computer program within statistical limits with known experimental values (23, 24) .
RESULTS
IgG and IgM metabolism. A summary of IgG and 1gM metabolism in ataxia telangiectasia is found in Tables II and III. Serum levels of IgG varied considerably. In two cases, distinctly high levels of IgG were found; these patients had been subject to recent and recurrent infection. One instance of abnormally low IgG was found; this patient had been subject to respiratory infection in 1908 Strober the distant past, though not in the several years 50 normal sera (2.6 ± 1.1 mg/ml). In one case, before study. IgG synthetic rates and catabolic an unusually low value was found (patient E.M.), rates were within normal limits in the two pa-and in one instance, a somewhat high value was tients with normal serum IgG levels. In those pa-found (patient R.McS.). In contrast to the contients with high serum IgG levels, fractional catatrol group, serum IgA was not detectable in any bolic rates were increased and, correspondingly, of the cases of ataxia telangiectasia; in addition, synthetic rates were greatly increased above nor-serum which had been concentrated fivefold was mal. In contrast, the patient with low serum IgG also devoid of IgA. level had a normal fractional catabolic rate and a As seen in Table IV , the fractional catabolic synthetic rate approximately two standard deviarate of IgA for the control group varied between tions below the norm.
14.4 and 33.8%o of the catabolic pool (plasma IgM levels were normal in three patients and pool) per day; the average fractional catabolic slightly elevated in two patients. The three pa-rate was 25% per day. Synthetic rates varied betients with normal IgM levels underwent turnover tween 3 and 55 mg/kg per day and averaged 24 studies with labeled IgM and showed normal fracmg/kg per day. tional catabolic and synthetic rates. Distribution
The IgA turnover data of the ataxia telangiecof IgM protein was likewise normal in these tasia group, Table V , fell into two categories. In patients.
the first category (represented by patients G.V.L. IgA metabolism. The mean serum IgA level and P.G.) very rapid catabolism of IgA was obin the control patient group (2.5 ± 1.4 mg/ml) served with computed fractional catabolic rates was close to the established mean in a panel of (A,.,) 4 and 20 times greater than that seen in the control group. These two patients were studied Calculated maximal IgA synthetic rates obtained with all three IgA preparations with virtually by assuming the presence of a serum concentraequivalent results. In the second group (patients tion just below that detectable by the methods G.N.L., D.R., and G.R.) the fractional catabolic used (0.01 mg/ml) were exceedingly low for all rates were within the range established by the five patients with ataxia telangiectasia (Table V) . control patient group.
Mechanism of rapid IgA degradation in pa- tients G.V.L. and P.G. A number of studies were performed to determine the cause of the accelerated IgA catabolism observed in patients G.V.L. and P.G. (a) Labeled IgA was incubated with sera from patients G.V.L. and P.G. overnight at 370C and then injected into control patients. Labeled IgA incubated in G.V.L. serum (two studies) was rapidly catabolized (Fig. 3) .
No hypercatabolism was demonstrated with the same IgA preparation incubated with normal serum or serum from patient P.G. (b) Sera from patients with ataxia telangiectasia and controls were mixed with labeled IgA in order to measure the capacity to precipitate IgA. G.V.L. serum, but not other ataxia telangiectasia sera or control sera, proved to have this capacity. Each milliliter of G.V.L. serum could precipitate about 4 x 1O4 mg of IgA. When rabbit anti-IgG was added to the incubation mixture to precipitate soluble complexes of IgG and IgA, a tenfold increase in IgA precipitation was obtained. IgG isolated from the serum of G.V.L. also brought about labeled IgA precipitation. Finally, precipitation of labeled IgA by G.V.L. serum was blocked by preincubation of serum with unlabeled IgA. (c) Immune precipitation was also studied with radioimmunoelectrophoresis. Patient sera were electrophoresed and reacted with anti-IgG and other antisera to serum proteins; after development of precipitation arcs, the agar plate was bathed in a medium containing labeled IgA. A radioautograph of the plate subsequently showed labeling of the IgG arc of patient G.V.L.; no other arcs were labeled. Alternatively, G.V.L. serum was electrophoresed and reacted against labeled IgA (placed in the trough); a labeled arc in the gamma region was found by radioautography ( Fig. 4) . Other ataxia telangiectasia sera showed no evidence of IgA binding by radioimmunoelectrophoresis. (d) Finally, ataxia telangiectasia serum-IgA interaction was studied with a modification of the C'la fixation and transfer test of Borsos and Rapp (25, 26) .4 This test measures the amount of antibody present by first fixing C'la to red cells with antibody and then measuring the amount of C'la fixed by transferring it to a defined red cell hemolysis system containing the other components of complement. The amount of C'la fixed is directly related to the number of antibody molecules originally present. In the present instance, a special C'la fixation and transfer system was set up, and antibody was detected by specific inhibition of the system. In this system, red cells were coated with IgA (an IgA isohemagglutinin) and mixed with C'la-fixing anti-IgA; C'la fixed was then quantitated and was an indicator of the amount of complement-fixing anti-IgA present. This reaction may be inhibited by preincubation of the IgA isohemagglutinin with a substance that will specifically react with it and thereby prevent binding of the IgA to the cell surface as well as subsequent fixation of C'la. Inhibition was obtained with both G.V.L. and P.G. serum but not with other ataxia telangiectasia sera or sera of other patients with serum IgA deficiency. It was determined that the G.V.L. serum contained at least 2.6 x 1012 anti-IgA molecules per ml of serum, whereas P.G. serum contained at least 2.1 x 1012 anti-IgA molecules per ml of serum. In sum, patient G.V.L. was shown to have a circulating serum factor that binds specifically to IgA and is a yG-globulin. Evidence for a similar factor in the serum of patient P.G. was provided by the C'la fixation and transfer test. Metabolism of IgA in patients with IgA myeloma and hypogammaglobulinemia (Table VI) .
The IgA fractional catabolic rates for the myeloma patient, the hypogammaglobulinemic patient, and the patient with isolated IgA deficiency were within the control range. In the myeloma patient (A.G.) the synthetic rate was 652 mg/kg per day or about 25 times the mean observed in the control group. The synthetic rates in the patients with no IgA (A.P. and B.H.) were < 0.08 mg/ kg per day or less than 0.32% of the control mean.
DISCUSSION
Patients with ataxia telangiectasia have a variable dysgammaglobulinemia, with occasional disorders of IgG and IgM concentration, and a frequent reduction or absence of IgA in the serum. In the present report, the metabolism of the immunoglobulins was studied in five patients with this disease.
IgG and IgM metabolism in ataxia telangiectasia. IgG metabolism in the five patients studied was variable. Survival of IgG (fractional catabolic rate) was normal in three of the five patients, including the two patients with the marked hypercatabolism of IgA. In two patients (both with somewhat elevated IgG levels), survival of IgG was shortened with fractional catabolic rates greater than three standard deviations above normal values. A similarly increased fractional catabolic rate may be seen in other patients with increased IgG levels, as in multiple myeloma (23, 27) . However, this may not be th4'sole explanation since in patient D.R. the serum IgG level of 23.6 mg/ml was associated with a fractional catabolic rate of 15.5%o /day; in other cases of hypergammaglobulinemia such catabolic rates are associated with far higher IgG levels (23) . Only one patient had a decreased IgG level, a finding sporadically found in other cases of ataxia telangiectasia (2, 6) ; in our pa- 1912 Strober, Wochner, Barlow, McFarlin, and Waldmann tient, the decreased IgG level was associated with a somewhat decreased synthetic rate and a normal fractional catabolic rate and was, therefore, a pure synthetic defect.
IgM metabolism was studied in three patients, two of whom had marked hypercatabolism of IgA. Serum levels, total body pools, and fractional turnover rates of this protein were normal. Hence, no abnormality of IgM metabolism was noted in these studies.
Normal IgA metabolism. IgA metabolism was studied in 12 control subjects. Synthetic rates varied between 2.7 and 55.0 mg/kg per day, and fractional catabolic rates ranged from 14 to 37% per day. This study of normal IgA metabolism compares roughly with those previously reported by Solomon and Tomasi (28) , who obtained fractional catabolic rates of approximately 37% per day.
It is seen that synthetic rates vary by a factor of 20, whereas catabolic rates vary by a factor of two at most; this means that differences in serum IgA levels among individuals primarily reflect variations in IgA synthesis and not rates of catabolism. It may be noted that the mean IgA synthetic rate of normal individuals (24 ± 15 mg/kg per day) is of the same order of magnitudes as the mean IgG synthetic rate (34 + 11 mg/kg per day) ; hence, the widely differing serum levels of IgA and IgG (2.6 + 1.1 vs. 12.0 + 2.6 mg/ml) are caused primarily by differing catabolic rates for these two proteins.
It has now been amply demonstrated that IgA is a prominent constituent of certain external secretions (i.e., saliva, colostrum, and nasal washings). Studies on the transport of labeled IgA into these secretions are consistent with the view that there is very considerable local production of IgA with release of IgA directly into the secretions.5
The synthetic rates calculated in metabolic turnover studies account for only those IgA molecules entering the circulating pool; these synthetic rates are therefore probably considerably less than the whole body synthetic rate of IgA, which includes synthesis of IgA destined solely for local secretion.
The normal IgA metabolic data illustrate certain important differences between IgG and IgA catabolism. First, IgG and IgA have similar intra and extravascular distribution ratios, and presumably, therefore, these molecules have equal exposure to catabolic sites. Yet IgA has a higher degradation rate than IgG by a factor of three or four. Second, the fractional rate of IgG catabolism may be affected by serum concentration, i.e., with hypogammaglobulinemia fractional catabolic rates are decreased and with hypergammaglobulinemia fractional catabolic rates are increased (23) . IgA catabolism is not apparently affected by concentration per se since the catabolic rates in subjects in the present study with low or absent IgA (without antibody to IgA) have normal fractional catabolic rates, and a subject with IgA myeloma likewise has a normal fractional catabolic rate. The differences in the catabolism of IgG and IgA imply that the catabolic mechanisms are unique for each of these proteins and are determined by the H-chain moieties of the molecules.
IgA metabolism in ataxia telangiectasia patients. Turnover studies in the patients with ataxia telangiectasia demonstrate that the serum IgA deficiency in ataxia telangiectasia is predominantly caused by decreased synthesis, with the additional factor of hypercatabolism observed in two of the cases. Synthetic rates could not be truly calculated since no serum IgA was detected; however, if one assumes an IgA concentration of 0.01 mg/ml (the maximal amount undetected), maximum synthetic rates are found which vary from 0.08 to 2.5 mg/kg per day. Fractional catabolic rate in patient G.V.L. was 500%o per day and in patient D.G. 90% per day. In the other three patients (G.N.L., D.R., and G.R.) normal survival was observed (mean: 23%o per day). It should be emphasized that the observed shortened survivals cannot, in themselves, explain the serum IgA levels found; even in the patient with a fractional catabolic rate of 500% per day the maximum synthetic rate possible would be approximately 2.5 mg/kg per day, still only 10% of the mean synthetic rate of the control group. Thus, a severe synthetic defect is seen in all of the patients studied and constitutes the most consistent and important metabolic finding.
The observed hypercatabolism of IgA in some patients with ataxia telangiectasia would appear to be due to the presence of a circulating factor which results in rapid elimination of the labeled Immunoglobulin Metabolism in Ataxia Telangiectasia IgA. That this circulating factor is an antibody is supported by the fact that precipitation of labeled IgA was obtained with the IgG of the patient G.V.L. and not with any other serum protein. Moreover, the precipitation reaction had specificity in that labeled IgG, IgM, or albumin was not precipitated in radioimmunoelectrophoresis studies. Evidence for the presence of antibody in patient P.G. is less complete. Here no radioactive immunoelectrophoretic band could be seen, but P.G. serum specifically reacted with IgA in the C'la fixation and transfer test. We conclude that circulating antibodies are quite likely present in patient G.V.L. and probably present in patient P.G.
The appearance of anti-IgA antibodies in patients deficient in IgA parallels the findings of several authors who have found circulating Gmspecific and non-Gm-specific anti-IgG within the IgM immunoglobulin class. This has been found in patients after repeated blood transfusions (29), after receiving gamma globulins (30) , or may occur without any known antigenic exposure (30, 31) . In the latter instance, sensitization by placentally transferred IgG has been postulated (31) .
Anti-IgA antibodies in these patients with ataxia telangiectasia may have developed from previous exposure to parenterally administered gamma globulin. Patient G.V.L., but not patient P.G., received gamma globulin injections in the past. Since IgA turnover studies followed IgM and IgG turnover studies in time, it is possible that sensitization occurred with small (indeed, undetectable) amounts of IgA contaminating IgM and IgG preparations used in the turnover experiments.
The patients with rapid IgA catabolism represent the first instance of an alteration in immunoglobulin survival caused by a circulating antibody. The appearance of such antibodies illustrates the fact that administration of immunoglobulins to dysgammaglobulinemic patients may not be possible since these patients can still produce antibodies to the deficient protein. The ability to give gamma globulin to agammaglobulinemic patients may, in part, be related to the fact that such patients cannot form antibodies in sufficient concentration to affect the survival of the injected materials.
